{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:33:37Z","timestamp":1791851617895,"version":"4.3.4"},"reference-count":71,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jocn-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.jocn.2015.03.059","type":"journal-article","created":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T17:15:25Z","timestamp":1438449325000},"page":"1568-1574","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Update on prolactinomas. Part 2: Treatment and management strategies"],"prefix":"10.1016","volume":"22","author":[{"given":"Anni","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Anderson","family":"Eloy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William T.","family":"Couldwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James K.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2015.03.059_b0005","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/er.2005-9998","article-title":"Advances in the treatment of prolactinomas","volume":"27","author":"Gillam","year":"2006","journal-title":"Endocr Rev"},{"key":"10.1016\/j.jocn.2015.03.059_b0010","doi-asserted-by":"crossref","first-page":"E2","DOI":"10.3171\/foc.2004.16.4.3","article-title":"Contemporary management of prolactinomas","volume":"16","author":"Liu","year":"2004","journal-title":"Neurosurg Focus"},{"key":"10.1016\/j.jocn.2015.03.059_b0015","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1365-2362.2010.02399.x","article-title":"Treatment for prolactinomas and hyperprolactinaemia: a lifetime approach","volume":"41","author":"Mann","year":"2011","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jocn.2015.03.059_b0020","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.bpobgyn.2007.08.002","article-title":"Hyperprolactinaemia","volume":"22","author":"Prabhakar","year":"2008","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.jocn.2015.03.059_b0025","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","article-title":"Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas","volume":"65","author":"Casanueva","year":"2006","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.jocn.2015.03.059_b0030","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s11060-013-1270-8","article-title":"Management of medically refractory prolactinoma","volume":"117","author":"Molitch","year":"2014","journal-title":"J Neurooncol"},{"key":"10.1016\/j.jocn.2015.03.059_b0035","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1056\/NEJMcp025334","article-title":"Clinical practice. Prolactinoma","volume":"349","author":"Schlechte","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2015.03.059_b0040","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1210\/jc.2007-0836","article-title":"Long-term management of prolactinomas","volume":"92","author":"Schlechte","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocn.2015.03.059_b0045","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.3171\/2011.1.FOCUS10317","article-title":"Endoscopic endonasal transsphenoidal surgery for functional pituitary adenomas","volume":"30","author":"Hofstetter","year":"2011","journal-title":"Neurosurg Focus"},{"key":"10.1016\/j.jocn.2015.03.059_b0050","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1530\/eje.0.1400043","article-title":"Trans-sphenoidal surgery for microprolactinoma: an acceptable alternative to dopamine agonists?","volume":"140","author":"Turner","year":"1999","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jocn.2015.03.059_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/B978-1-4160-6839-6.10019-X","article-title":"Prolactinomas","author":"Liu","year":"2012"},{"key":"10.1016\/j.jocn.2015.03.059_b0060","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.endonu.2012.11.005","article-title":"Clinical guidelines for diagnosis and treatment of prolactinoma and hyperprolactinemia","volume":"60","author":"Halperin Rabinovich","year":"2013","journal-title":"Endocrinol Nutr"},{"key":"10.1016\/j.jocn.2015.03.059_b0065","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.beem.2009.05.003","article-title":"Pituitary tumours: the prolactinoma","author":"Colao","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.jocn.2015.03.059_b0070","first-page":"104","article-title":"Update in prolactinomas","volume":"68","author":"Kars","year":"2010","journal-title":"Neth J Med"},{"key":"10.1016\/j.jocn.2015.03.059_b0075","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2251-6581-12-3","article-title":"Giant prolactinoma: case report and review of literature","volume":"12","author":"Rahmanian","year":"2013","journal-title":"J Diabetes Metab Disord"},{"key":"10.1016\/j.jocn.2015.03.059_b0080","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1053\/beem.1999.0030","article-title":"Clinical management of prolactinomas","volume":"13","author":"Webster","year":"1999","journal-title":"Baillieres Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.jocn.2015.03.059_b0085","first-page":"3053","article-title":"Primary medical therapy of micro- and macroprolactinomas in men","volume":"85","author":"Pinzone","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocn.2015.03.059_b0090","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson\u2019s disease","volume":"356","author":"Zanettini","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2015.03.059_b0095","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.mpmed.2009.05.003","article-title":"Prolactin disorders","volume":"37","author":"Martin","year":"2009","journal-title":"Medicine"},{"key":"10.1016\/j.jocn.2015.03.059_b0100","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/BF03345662","article-title":"Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies","volume":"31","author":"Bogazzi","year":"2008","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.jocn.2015.03.059_b0105","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1111\/j.1742-1241.2008.01779.x","article-title":"Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia","volume":"62","author":"Bogazzi","year":"2008","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jocn.2015.03.059_b0110","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11102-008-0134-2","article-title":"Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas","volume":"12","author":"Vallette","year":"2009","journal-title":"Pituitary"},{"key":"10.1016\/j.jocn.2015.03.059_b0115","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1586\/erc.09.167","article-title":"Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern?","volume":"8","author":"Vallette","year":"2010","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.jocn.2015.03.059_b0120","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1530\/EJE-06-0646","article-title":"Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men","volume":"156","author":"Shimon","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jocn.2015.03.059_b0125","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11154-005-5220-4","article-title":"Long-term management of prolactinomas\u2013use of long-acting dopamine agonists","volume":"6","author":"Cook","year":"2005","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.jocn.2015.03.059_b0130","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ecl.2007.10.013","article-title":"Hyperprolactinemia and prolactinomas","volume":"37","author":"Mancini","year":"2008","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.jocn.2015.03.059_b0135","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJM199410063311403","article-title":"A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group","volume":"331","author":"Webster","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2015.03.059_b0140","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.3171\/2010.11.JNS101369","article-title":"Dopamine agonist-resistant prolactinomas","volume":"114","author":"Oh","year":"2011","journal-title":"J Neurosurg"},{"key":"10.1016\/j.jocn.2015.03.059_b0145","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1445-5994.2010.02410.x","article-title":"Dopamine agonists in the treatment of prolactinoma: are they still first choice?","volume":"41","author":"Ogilvie","year":"2011","journal-title":"Intern Med J"},{"key":"10.1016\/j.jocn.2015.03.059_b0150","doi-asserted-by":"crossref","first-page":"996","DOI":"10.4103\/2230-8210.122608","article-title":"Pregnancy and pituitary disorders: challenges in diagnosis and management","volume":"17","author":"Laway","year":"2013","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.jocn.2015.03.059_b0155","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocn.2015.03.059_b0160","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.beem.2011.05.011","article-title":"Prolactinoma in pregnancy","volume":"25","author":"Molitch","year":"2011","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.jocn.2015.03.059_b0165","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1210\/jc.2009-1238","article-title":"Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis","volume":"95","author":"Dekkers","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocn.2015.03.059_b0170","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/j.1365-2265.2011.04136.x","article-title":"Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma","author":"Barber","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.jocn.2015.03.059_b0175","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1210\/jc.2008-2103","article-title":"Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy","volume":"94","author":"Kharlip","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocn.2015.03.059_b0180","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa022657","article-title":"Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia","author":"Colao","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2015.03.059_b0185","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11102-011-0303-6","article-title":"Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experience","volume":"15","author":"Anagnostis","year":"2012","journal-title":"Pituitary"},{"key":"10.1016\/j.jocn.2015.03.059_b0190","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2265.2007.02905.x","article-title":"Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy","volume":"67","author":"Colao","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.jocn.2015.03.059_b0195","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1530\/EJE-12-0236","article-title":"Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients","volume":"167","author":"Vroonen","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jocn.2015.03.059_b0200","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s11102-009-0168-0","article-title":"Secondary resistance to cabergoline therapy in a macroprolactinoma: a case report and literature review","volume":"14","author":"Behan","year":"2011","journal-title":"Pituitary"},{"key":"10.1016\/j.jocn.2015.03.059_b0205","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/BF03347092","article-title":"Resistant prolactinomas","volume":"34","author":"Vasilev","year":"2011","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.jocn.2015.03.059_b0210","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1210\/jcem.86.11.8054","article-title":"Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy","volume":"86","author":"Di Sarno","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocn.2015.03.059_b0215","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/j.1365-2265.2012.04373.x","article-title":"Temozolomide in the management of dopamine agonist-resistant prolactinomas","volume":"76","author":"Whitelaw","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.jocn.2015.03.059_b0220","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jocn.2014.12.007","article-title":"The role of temozolomide in the treatment of aggressive pituitary tumors","volume":"22","author":"Liu","year":"2015","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.jocn.2015.03.059_b0225","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1056\/NEJM200403043501019","article-title":"Prolactinomas","volume":"350","author":"Couldwell","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2015.03.059_b0230","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1530\/EJE-07-0248","article-title":"Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients","volume":"158","author":"Kreutzer","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jocn.2015.03.059_b0235","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1023\/A:1012905415868","article-title":"Current management of prolactinomas","volume":"54","author":"Nomikos","year":"2001","journal-title":"J Neurooncol"},{"key":"10.1016\/j.jocn.2015.03.059_b0240","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/BF01815444","article-title":"Present status of neurosurgery in the treatment of prolactinomas","volume":"8","author":"Fahlbusch","year":"1985","journal-title":"Neurosurg Rev"},{"key":"10.1016\/j.jocn.2015.03.059_b0245","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/00006123-199902000-00006","article-title":"Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results","volume":"44","author":"Tyrrell","year":"1999","journal-title":"Neurosurgery"},{"key":"10.1016\/j.jocn.2015.03.059_b0250","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1023\/B:PITU.0000044631.89535.48","article-title":"Medical and surgical management of microprolactinoma","volume":"7","author":"Couldwell","year":"2004","journal-title":"Pituitary"},{"key":"10.1016\/j.jocn.2015.03.059_b0255","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s11102-010-0283-y","article-title":"Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists","volume":"14","author":"Babey","year":"2011","journal-title":"Pituitary"},{"key":"10.1016\/j.jocn.2015.03.059_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/S1042-3680(02)00090-6","article-title":"Role of surgery in the treatment of microprolactinomas","volume":"14","author":"Couldwell","year":"2003","journal-title":"Neurosurg Clin N Am"},{"key":"10.1016\/j.jocn.2015.03.059_b0265","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3171\/jns.2002.97.2.0307","article-title":"Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery","volume":"97","author":"Amar","year":"2002","journal-title":"J Neurosurg"},{"key":"10.1016\/j.jocn.2015.03.059_b0270","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.beem.2009.05.002","article-title":"Surgical treatment of pituitary tumours","volume":"23","author":"Buchfelder","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.jocn.2015.03.059_b0275","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.clineuro.2013.02.016","article-title":"Transsphenoidal microsurgical results of female patients with prolactinomas","volume":"115","author":"Ikeda","year":"2013","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.jocn.2015.03.059_b0280","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1530\/EJE-09-0493","article-title":"Gamma knife radiosurgery: a safe and effective salvage treatment for pituitary tumours not controlled despite conventional radiotherapy","volume":"161","author":"Swords","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jocn.2015.03.059_b0285","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.3171\/foc.2003.14.5.13","article-title":"Stereotactic radiosurgery for hypersecreting pituitary tumors: part of a multimodality approach","volume":"14","author":"Jane","year":"2003","journal-title":"Neurosurg Focus"},{"key":"10.1016\/j.jocn.2015.03.059_b0290","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.nec.2012.06.010","article-title":"Medical versus surgical management of prolactinomas","volume":"23","author":"Oh","year":"2012","journal-title":"Neurosurg Clin N Am"},{"key":"10.1016\/j.jocn.2015.03.059_b0295","first-page":"316","article-title":"The stereotaxic method and radiosurgery of the brain","volume":"102","author":"Leksell","year":"1951","journal-title":"Acta Chir Scand"},{"key":"10.1016\/j.jocn.2015.03.059_b0300","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3171\/jns.2005.102.4.0678","article-title":"Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and role in the neurosurgical treatment armamentarium","volume":"102","author":"Sheehan","year":"2005","journal-title":"J Neurosurg"},{"key":"10.1016\/j.jocn.2015.03.059_b0305","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1210\/jc.2008-2772","article-title":"Long-term results of stereotactic radiosurgery in secretory pituitary adenomas","volume":"94","author":"Castinetti","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocn.2015.03.059_b0310","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.4103\/2152-7806.95419","article-title":"Comprehensive review of stereotactic radiosurgery for medically and surgically refractory pituitary adenomas","volume":"3","author":"Kim","year":"2012","journal-title":"Surg Neurol Int"},{"key":"10.1016\/j.jocn.2015.03.059_b0315","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11102-012-0376-x","article-title":"Gamma knife stereotactic radiosurgery for drug resistant or intolerant invasive prolactinomas","volume":"16","author":"Liu","year":"2013","journal-title":"Pituitary"},{"key":"10.1016\/j.jocn.2015.03.059_b0320","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3171\/jns.2000.93.supplement_3.0010","article-title":"Gamma knife radiosurgery as a primary treatment for prolactinomas","volume":"93","author":"Pan","year":"2000","journal-title":"J Neurosurg"},{"key":"10.1016\/j.jocn.2015.03.059_b0325","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1227\/01.NEU.0000223445.22938.BD","article-title":"Gamma knife radiosurgery for medically and surgically refractory prolactinomas","volume":"59","author":"Pouratian","year":"2006","journal-title":"Neurosurgery"},{"key":"10.1016\/j.jocn.2015.03.059_b0330","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/1754-9485.12257","article-title":"Single-centre experience of stereotactic radiosurgery and fractionated stereotactic radiotherapy for prolactinomas with the linear accelerator","volume":"59","author":"Wilson","year":"2015","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.jocn.2015.03.059_b0335","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.wneu.2010.05.007","article-title":"Gamma knife radiosurgery for patients with prolactin-secreting pituitary adenomas","volume":"74","author":"Tanaka","year":"2010","journal-title":"World Neurosurg"},{"key":"10.1016\/j.jocn.2015.03.059_b0340","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3171\/jns.2000.93.supplement_3.0014","article-title":"Gamma knife radiosurgery for prolactinomas","volume":"93","author":"Landolt","year":"2000","journal-title":"J Neurosurg"},{"key":"10.1016\/j.jocn.2015.03.059_b0345","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.3171\/foc.2003.14.5.12","article-title":"Hypophysial transposition (hypophysopexy) for radiosurgical treatment of pituitary tumors involving the cavernous sinus. Technical note","volume":"14","author":"Liu","year":"2003","journal-title":"Neurosurg Focus"},{"key":"10.1016\/j.jocn.2015.03.059_b0350","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3171\/2011.2.JNS10566","article-title":"Endocrinological outcome after pituitary transposition (hypophysopexy) and adjuvant radiotherapy for tumors involving the cavernous sinus","volume":"115","author":"Taussky","year":"2011","journal-title":"J Neurosurg"},{"key":"10.1016\/j.jocn.2015.03.059_b0355","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1023\/A:1023313232296","article-title":"Hypophysopexy technique for radiosurgical treatment of cavernous sinus pituitary adenoma","volume":"5","author":"Couldwell","year":"2002","journal-title":"Pituitary"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586815002763?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586815002763?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T00:19:57Z","timestamp":1567037997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586815002763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":71,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0967586815002763"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2015.03.059","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on prolactinomas. Part 2: Treatment and management strategies","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2015.03.059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}